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Predictors of Early, Late, and Very Late
Stent Thrombosis After Primary
Percutaneous Coronary Intervention
With Bare-Metal and Drug-Eluting Stents for
ST-Segment Elevation Myocardial Infarction
Bruce Brodie, MD,* Yashashwi Pokharel, MD,† Ankit Garg, MD,† Grace Kissling, PHD,‡
harles Hansen, MA,† Sally Milks, RN,* Michael Cooper, MD,*
hristopher McAlhany, MD,* Tom Stuckey, MD*
reensboro and Research Triangle Park, North Carolina
Objectives The purpose of this study was to evaluate the frequency and predictors of stent throm-
bosis (ST) after stenting for ST-segment elevation myocardial infarction (STEMI).
Background Stent thrombosis remains a major concern with STEMI patients treated with primary
percutaneous coronary intervention.
Methods Consecutive patients (N  1,640) undergoing stenting for STEMI were prospectively en-
rolled in our database and followed for 1 to 15 years. Bare-metal stents were implanted from 1995
to 2002, and drug-eluting and bare-metal stents were implanted from 2003 to 2009. Stent thrombo-
sis was deﬁned as deﬁnite or probable.
Results Our population had a high risk proﬁle, including a high incidence of Killip class III to IV
(11.5%) and STEMI due to ST (10.2%). Stent thrombosis occurred in 124 patients, including 42 with
early ST (0 to 30 days), 35 with late ST (31 days to 1 year), and 47 with very late ST (1 year). The
frequency of ST was 2.7% at 30 days, 5.2% at 1 year, and 8.3% at 5 years. Independent predictors of
early or late ST were STEMI due to ST (hazard ratio [HR]: 4.38, 95% conﬁdence interval [CI]: 2.27 to
8.45), small stent size (HR: 2.44, 95% CI: 1.49 to 4.00), Killip class III to IV (HR: 2.39, 95% CI: 1.30 to
4.40), and reperfusion time 2 h (HR: 2.09, 95% CI: 1.03 to 4.24). Drug-eluting stent was the only
independent predictor of very late ST (HR: 3.73, 95% CI: 1.81 to 7.88).
Conclusions Stent thrombosis after primary percutaneous coronary intervention is relatively fre-
quent and continues to increase out to 5 years. New strategies are needed to prevent ST in STEMI
patients, and targeted therapies are needed in patients identiﬁed at highest risk. (J Am Coll
Cardiol Intv 2012;5:1043–51) © 2012 by the American College of Cardiology Foundation
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1044The use of coronary stents has become the preferred therapy
with primary percutaneous coronary intervention (PCI) for
ST-segment elevation myocardial infarction (STEMI).
This is based on data showing that stents have been able to
reduce ischemic-driven target vessel revascularization and
angiographically documented restenosis and re-occlusion
(1,2). Unfortunately, stent thrombosis (ST) is more fre-
quent after stenting for STEMI than after elective stenting
with both drug-eluting stents (DES) and bare-metal stents
See page 1052
(BMS) (3–7). Data from the Thoraxcenter Registry have shown
significantly higher ST rates at 3 years after stenting for STEMI
versus elective stenting (3.3% vs. 1.1%, p  0.0009), and data
from both the Thoraxcenter Registry and the SCAAR registry
(Swedish Coronary Angiography and Angioplasty Registry) have
shown higher adjusted rates of ST
after stenting for STEMI versus
elective stenting (adjusted hazard
ratio [HR]: 3.10, 95% confidence
interval [CI]: 1.80 to 5.34, and HR:
2.57, 95% CI: 1.82 to 3.62, respec-
tively) (6,7). The HORIZONS-
AMI (Harmonizing Outcomes
with RevascularIZatiON and
Stents in Acute Myocardial Infarc-
tion) trial found a high frequency of
ST with both DES and BMS at 3
years (4.8% vs. 4.3%, p  0.68),
which was associated with a high
incidence of reinfarction (71.8%)
and short-term mortality (16.0%)
(8,9). Although this trial did not
show any difference in the fre-
quency of ST between DES and
BMS, there is still concern that very
late ST (1 year) might be more frequent with DES than BMS,
because of increased frequency of late stent malapposition and
poor healing of DES after primary PCI (10–12). For all these
reasons, ST after stenting for STEMI has been a major concern.
We have prospectively enrolled STEMI patients treated
with primary PCI into an ongoing database dating back to
the early use of stents with STEMI in 1995. This has
allowed for long-term follow-up and has provided a unique
opportunity to evaluate early, late, and very late ST. The
purpose of this study is to evaluate the frequency and
predictors of early, late, and very late ST after stenting for
STEMI.
Methods
Study population. The study population consists of 1,640
Abbreviations
and Acronyms
BMS  bare-metal stent(s)
CI  confidence interval
DES  drug-eluting stent(s)
GPI  glycoprotein IIb/IIIa
platelet inhibitor
HR  hazard ratio
MI  myocardial infarction
PCI  percutaneous
coronary intervention
PES  paclitaxel-eluting
stent(s)
RT  reperfusion time
ST  stent thrombosis
STEMI  ST-segment
elevation myocardial
infarctionconsecutive patients with STEMI treated with primary PCIat our institution from 1995 through 2009 who received a
stent or who had STEMI due to ST. Patients were included
in our registry if they had electrocardiographic ST-segment
elevation1 mm in2 contiguous leads or new left bundle
branch block, symptoms of 12-h duration (12 h for
persistent ischemic symptoms or hemodynamic compro-
mise), and were treated with primary PCI.
Treatment protocol. Patients were treated with contempo-
rary standards of care for primary PCI. In the early years,
this included aspirin, unfractionated heparin, and glyco-
protein IIb/IIIa platelet inhibitors and, in very recent years,
included aspirin and bivalirudin, usually without glyco-
protein IIb/IIIa platelet inhibitors. Ticlopidine (in the early
years) or clopidogrel were given immediately before or at the
time of PCI. Bare-metal stents were used exclusively from
1995 to 2003, and DES or BMS were used from 2003 to
2009 at the discretion of the operator. Of 410 patients who
received DES, 366 stents were first-generation DES
(sirolimus-eluting, paclitaxel-eluting, or zotarolimus-
eluting stents), and 44 were second-generation stents
(everolimus-eluting stents).
Data collection, clinical follow-up, and deﬁnitions. Patients
were enrolled prospectively into the database from 1995
through 2009. Procedural data were assessed and entered by
the interventional cardiologist at the time of the PCI, and
hospital outcomes were assessed from chart reviews on an ongoing
basis. Follow-up events were obtained from reviews of medical
records and telephone contact every year. Medical records for each
patient were reviewed to identify all readmissions for acute
coronary syndromes and all readmissions resulting in mortality.
Stent thrombosis was defined as definite or probable ST
according to the Academic Research Consortium (ARC) defini-
tion (13). Definite ST occurred when there was an acute coronary
syndrome with angiographic confirmation of thrombus within the
stent with partial or total occlusion of the stent. Probable ST
occurred when there was an infarct in the territory of the
stented vessel without angiographic confirmation or when
there was unexplained sudden death within 30 days. Early ST
was defined as ST occurring from 0 to 30 days, late ST was
defined as ST occurring from 31 days to 1 year, and very late
ST was defined as ST occurring after 1 year.
Stent type was classified as DES if a new DES was
implanted and as BMS if a new BMS was implanted with
the primary PCI for STEMI. In patients who had STEMI
due to ST in whom no new stent was implanted, stent type
was classified as DES or BMS depending on the type of
stent originally implanted.
Statistical analyses. Statistical comparisons of categorical vari-
ables were performed with the chi-square or Fisher exact test,
as appropriate. Frequencies of stent thromboses were assessed
by Kaplan-Meier estimates at 30 days, 1 year, and 5 years, and
comparisons of frequencies in patients with and without
selected variables were made with log-rank statistics. Land-
mark analyses were performed to compare frequencies of late
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1045ST (31 days to 1 year) and very late ST (1 to 5 years) in
patients with and without selected variables. Patients who
survived for 30 days without ST were included in landmark
analyses for late ST, and patients who survived for 1 year
without ST were included in the landmark analyses for very
late ST. Multivariable analyses of predictors of ST were
performed with Cox proportional hazards regression models.
Clinical and angiographic variables with p values 0.1 on
nivariable analyses (Table 1) were entered into the Cox
egression models. In addition, diabetes and stent type were
ntered into the models because of their clinical relevance. Back-
ard elimination at alpha  0.05 was used to select significant
redictors. All analyses were performed with SPSS (version 19.0,
BM Incorporated, Armonk, New York) and SAS (version 9.2,
AS Institute, Cary, North Carolina) software.
esults
From 1995 through 2009, 1,640 consecutive patients un-
dergoing primary PCI for STEMI were treated with BMS
(n  1,147) or DES (n  410) or had STEMI due to ST
Table 1. Baseline Clinical and Angiographic Variables and Procedural Varia
ST
(n  124)
No ST
(n  1,516)
Clinical variables
All patients
Age 70 yrs 22 (17.7%) 355 (23.4%)
Women 29 (23.4%) 463 (30.5%)
Diabetes 19 (15.3%) 241 (15.9%)
Insulin-dependent diabetes 5 (4.0%) 59 (3.9%)
Current smoker 54 (43.5%) 746 (49.2%)
Prior infarction 32 (25.8%) 236 (15.6)
Prior bypass surgery 9 (7.3%) 78 (5.1%)
Anterior infarction 36 (29.0%) 560 (36.9%)
Killip class III–IV 16 (12.9%) 173 (11.4%)
Angiographic and procedural variables
3-vessel coronary disease 30 (24.2%) 348 (23.0%)
LVEF 40% 24 (20.3%) 297 (20.7%)
Infarct vessel  vein graft 5 (4.0%) 37 (2.4%)
TIMI ﬂow grade 0–1 pre-PCI 92 (74.2%) 1,149 (75.8%)
TIMI ﬂow grade 0–2 post-PCI 3 (2.4%) 74 (4.9%)
Small stent size (3.0 mm) 33 (26.6%) 314 (20.8%)
Multiple stents 28 (28.6%) 342 (28.3%)
Drug-eluting stent* 29 (25.2%) 381 (26.4%)
GPI used 93 (75.0%) 1,030 (67.9%)
STEMI due to ST 22 (17.7%) 145 (9.6%)
Reperfusion time 2 h 15 (12.1%) 123 (8.1%)
Values are n (%). Comparison of event rates in patients with and without the index variable are mad
thrombosis (ST) at 1 and 5 years.
GPI glycoprotein IIb/IIIa platelet inhibitor; LVEF left ventricular ejection fraction; PCI percuIn Myocardial Infarction.and underwent PCI but did not receive a new stent (n  83).
Patients were followed prospectively for 1 to 15 years. Clinical
follow-up was complete or out to at least 4 years in 85% of
patients, with a median follow-up time of 3.7 years. Stent
thrombosis occurred in 124 patients, including 42 patients with
early ST (30 days), 35 patients with late ST (31 days to 1
year), and 47 patients with very late ST (1 year). The
cumulative frequency of ST by Kaplan-Meier estimates was
2.7% at 30 days, 5.2% at 1 year, and 8.3% at 5 years (Fig. 1).
Of the 42 patients with early ST, 34 were definite, and 8
were probable, including 5 with sudden unexplained death
within 30 days. Of the 82 patients with late or very late ST,
81 were definite, and 1 was probable ST. Compliance with
dual antiplatelet therapy at the time of ST was present in
60% of patients with early ST, 52% of patients with late ST,
and 12% of patients with very late ST.
Baseline clinical and angiographic variables and frequency of ST.
Patients with ST have a higher frequency of prior myocar-
dial infarction (MI) and STEMI due to ST (Table 1). The
cumulative frequencies of ST out to 5 years by Kaplan-Meier
Value
Kaplan-Meier Frequency of ST*
Variable Present Variable Absent
Log-Rank
p Value1 Yr 5 Yrs 1 Yr 5 Yrs
5.2% 8.3%
.15 5.3% 7.6% 5.2% 8.7% 0.41
.095 4.1% 6.9% 5.7% 9.2% 0.10
.87 7.3% 9.4% 4.9% 8.3% 0.76
.94 9.7% 9.6% 5.1% 8.4% 0.70
.23 5.1% 8.7% 5.3% 8.2% 0.44
.003 11.1% 14.9% 4.1% 7.3% 0.001
.31 8.8% 9.0% 5.0% 8.5% 0.36
.078 4.7% 6.9% 5.5% 9.3% 0.18
.62 11.5% 10.5% 4.6% 8.1% 0.041
.75 6.4% 9.0% 4.9% 8.3% 0.64
.92 7.3% 8.7% 4.6% 8.3% 0.50
.43 10.7% 10.9% 5.1% 8.4% 0.26
.69 5.0% 8.8% 5.7% 8.4% 0.78
.21 3.7% 10.2% 5.3% 8.5% 0.59
.13 8.9% 10.6% 4.3% 7.9% 0.010
.95 6.7% 9.0% 5.0% 9.6% 0.91
.78 4.2% 12.8% 5.2% 7.4% 0.26
.104 6.0% 9.5% 3.5% 6.2% 0.039
.004 13.6% 16.9% 4.4% 7.6% 0.001
.12 10.2% 11.8% 4.8% 8.2% 0.080
og-rank tests. *Values listed represent Kaplan-Meier estimates of the cumulative frequency of stent
coronary intervention; STEMI ST-segment elevationmyocardial infarction; TIMI Thrombolysisbles
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1046analyses were significantly greater in patients with prior MI,
Killip class III to IV, small stent size (3.0 mm), glycoprotein
IIb/IIIa inhibitor use, and STEMI due to ST (Table 1).
Patients with Killip class III to IV comprised 11.5% of
our study population, and patients with STEMI due to ST
comprised 10.2% of our study population.
Univariable correlates of early, late, and early or late ST and
very late ST. Prior MI, Killip class III to IV, 3-vessel
coronary disease, small stent size (3.0 mm), and STEMI
due to ST were significant univariable correlates of increased
incidence of early ST (30 days) by Kaplan-Meier analyses
(Table 2).
Prior MI, Killip class III to IV, STEMI due to ST, and
reperfusion time (RT) 2 h were significant univariable
correlates of increased frequency of late ST (landmark
analyses 31 days to 1 year) (Table 2).
Prior MI, Killip class III to IV, small stent size (3.0
mm), use of glycoprotein IIb/IIIa inhibitors, STEMI due to
ST, and RT 2 h were significant univariable correlates of
early or late ST (ST from Day 0 through 1 year) (Figs. 2A
to 2E, Table 2).
The only significant univariable correlate of very late ST
(landmark analyses 1 year) was the use of a DES com-
pared with a BMS (7.0% vs. 1.7% from 1 to 5 years, p 
0.001) (Fig. 3). Because comparison of outcomes from
different time periods could introduce bias when comparing
DES with BMS (BMS were implanted from 1995 to 2009,
whereas DES were implanted from 2003 to 2009), we
analyzed the period 2003 to 2009 when both types of stents
were being implanted. During this period there was a trend
for an increased incidence of very late ST with DES (7.0%
vs. 2.9% from 1 to 5 years, p  0.066).
Multivariable predictors of early, late, early or late, and very
late ST. ST-segment elevation myocardial infarction due to
Figure 1. Cumulative Frequency of ST After Primary Percutaneous
Coronary Intervention With Stenting in All Patients
The curve shows Kaplan-Meier estimates of deﬁnite or probable stent
thrombosis (ST) (Academic Research Consortium criteria) out to 5 years.ST, Killip class III to IV, and small stent size (3.0 mm)were significant multivariable predictors of early ST (0 to 30
days) by Cox regression (Table 3). Reperfusion time 2 h,
prior MI, and diabetes were significant multivariable pre-
dictors of late ST (31 to 365 days). ST-segment elevation
myocardial infarction due to ST, small stent size (3.0
mm), Killip class III to IV, and RT 2 h were significant
multivariable predictors of early or late ST (0 to 365 days).
The use of a DES compared with a BMS was the only
significant independent predictor of very late ST when all
years were analyzed. When we analyzed only the years when
both BMS and DES were implanted (2003 to 2009), there
was a trend for higher rates of very late ST with DES (HR:
2.36, 95% CI: 0.92 to 6.03, p  0.073).
Discussion
The major findings of this study are: 1) the frequency of ST
after DES and BMS for STEMI is relatively high and
continues to increase out to 5 years; and 2) the major
predictors of early or late ST (0 to 1 year) are STEMI due
to ST, small stent size (3.0 mm), Killip class III to IV, and
RT2 h; the only predictor of very late ST (1 year) is the
use of DES versus BMS.
A number of studies have shown that the frequency of ST
after stent implantation for STEMI is relatively high and
that implantation of stents for STEMI is one of the
strongest independent predictors of subsequent ST (3–8).
In addition, there are several studies that have shown that
the cumulative frequency of ST continues to increase out to
3 to 5 years and beyond (7,8,14). The frequency of ST in
our study is higher than the frequency in the HORIZONS-
AMI study and other studies, and this might be related to
the inclusion of relatively large numbers of patients at high
risk for ST, including patients with Killip class III to IV and
patients with STEMI due to ST. Also, our study population
is from an all-inclusive clinical setting rather than a random-
ized controlled trial, and as a consequence, our population
might have poorer compliance with dual antiplatelet therapy
and other therapies. Follow-up is longer in our study than
previous studies and documents that the cumulative frequency
of ST continues to increase out to at least 5 years.
Several studies have evaluated predictors of ST after
stenting for STEMI. Smit et al. (17) evaluated 1,548
STEMI patients treated with stenting and found that Killip
class I was the only significant predictor of ST at 1 year.
Ergelen et al. (18) evaluated 1,960 STEMI patients treated
with stenting and found that stent diameter 3 mm,
current smoker, and diabetes were the only significant
independent predictors of 30-day ST. Dangas et al. (19)
evaluated predictors of ST out to 2 years in 3,203 STEMI
patients from the HORIZONS-AMI trial. Significant in-
dependent predictors of early ST (30 days) were insulin-
dependent diabetes, baseline Thrombolysis In Myocardial
Infarction flow grade 0 to 1, higher baseline platelet count,
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1047no pre-randomization heparin, and low (300 vs. 600 mg)
clopidogrel loading dose. Predictors of late ST (30 days to 1
year) were insulin-dependent diabetes, prior MI, and cur-
rent smoking. Predictors of very late ST (1 to 2 years) were
insulin-dependent diabetes, history of prior PCI, higher
baseline platelet count, and use of heparin and glycoprotein
IIb/IIIa inhibitor versus bivalirudin. Similar to these studies,
our study found that Killip class III to IV, small stent size
3.0 mm, and prior MI were significant predictors of ST.
Diabetes was an independent predictor of late ST, and there
were trends for more early or late ST in patients with
insulin-dependent diabetes. We also found that early RT was
a significant predictor of early or late ST. The reasons for this
are not clear. Early reperfusion was not a significant predictor
of ST in the HORIZONS-AMI trial (19). It is possible that
patients with early reperfusion have more viable myocardium
and are more likely to present with an acute coronary syndrome
and ST, rather than silent occlusion.
The use of a DES versus a BMS was the only significant
predictor of very late ST in our study. Of the previous
studies discussed in the preceding text, only the
Table 2. Univariable Correlates of Frequency of Early, Late, and Early or La
Early ST
Variable
Present
Variable
Absent p Value
Clinical variables
Age 70 years 2.9% 2.6% 0.81
Women 2.6% 2.7% 0.86
Diabetes 2.9% 2.7% 0.86
Insulin-dependent diabetes 5.4% 2.6% 0.24
Current smoker 2.2% 3.2% 0.25
Prior infarction 5.2% 2.2% 0.008
Prior bypass surgery 4.8% 2.6% 0.22
Anterior infarction 2.9% 2.6% 0.81
Killip class III–IV 6.8% 2.3% 0.001
Angiographic and procedural variables
3-vessel coronary disease 4.2% 2.2% 0.047
LVEF 40% 3.8% 2.4% 0.21
Infarct vessel  vein graft 4.9% 2.6% 0.330
TIMI ﬂow grade 0–1 pre-PCI 2.8% 2.3% 0.62
TIMI ﬂow grade 0–2 post-PCI 0.0% 2.8% 0.17
Small stent size (3.0 mm) 5.4% 2.0% 0.001
Multiple stents 3.7% 2.5% 0.21
Drug-eluting stent 1.8% 2.9% 0.21
GPI used 3.1% 1.8% 0.15
STEMI due to ST 7.8% 2.1% 0.001
Reperfusion time 2 h 3.8% 2.6% 0.40
Values listed represent Kaplan-Meier estimates of the cumulative frequency of early ST (30 days), l
estimates of the cumulative frequency of ST in patients with and without the index variable with th
Abbreviations as in Table 1.HORIZONS-AMI study evaluated predictors of very lateST, and the type of stent used (paclitaxel-eluting stent
[PES] vs. BMS) was not a significant predictor (19).
However, later follow-up out to 3 years in the
HORIZONS-AMI study did show trends for increased
rates of very late ST from 1 to 3 years with PES (PES 1.7%
vs. BMS 0.9%, p  0.12) (8). Other studies have shown
conflicting results. Violini et al. (20) reporting from the
SESAMI (Sirolimus-Eluting Stent Versus Bare-Metal
Stent in Acute Myocardial Infarction) trial and Spaulding et
al. (14) reporting from TYPHOON (Trial to Assess the
Use of the Cypher Stent in Acute Myocardial Infarction
Treated with Balloon Angioplasty) found no difference in
very late ST from 1 to 5 years between sirolimus-eluting
stent and BMS. However, Vink et al. (15) found a higher
frequency of very late ST with PES compared with BMS from
1 to 5 years in the PASSION (Paclitaxel Eluting Stent Versus
Conventional Stent in ST-segment Elevation Myocardial
Infarction) trial, and Brodie et al. (16) have previously reported
a higher frequency of very late ST in patients with DES
versus BMS in their large primary PCI registry. There
has been concern about very late ST when DES are
*
Frequency
Late ST Early or Late ST
ariable
resent
Variable
Absent p Value
Variable
Present
Variable
Absent
Log-Rank
p Value
2.5% 2.6% 0.86 5.3% 5.2% 0.95
1.5% 3.1% 0.10 4.1% 5.7% 0.22
4.5% 2.3% 0.071 7.3% 4.9% 0.18
4.5% 2.5% 0.42 9.7% 5.1% 0.15
2.9% 2.2% 0.40 5.1% 5.3% 0.78
6.2% 1.9% 0.001 11.1% 4.1% 0.001
4.3% 2.5% 0.34 8.8% 5.0% 0.12
1.9% 3.0% 0.23 4.7% 5.5% 0.54
5.1% 2.4% 0.035 11.5% 4.6% 0.001
2.3% 2.7% 0.78 6.4% 4.9% 0.20
3.7% 2.3% 0.21 7.3% 4.6% 0.074
6.1% 2.5% 0.20 10.7% 5.1% 0.11
2.3% 3.5% 0.23 5.0% 5.7% 0.66
3.7% 2.6% 0.47 3.7% 5.3% 0.56
3.7% 2.3% 0.16 8.9% 4.3% 0.001
3.1% 2.6% 0.72 6.7% 5.0% 0.24
2.5% 2.3% 0.90 4.2% 5.2% 0.35
3.0% 1.7% 0.15 6.0% 3.5% 0.042
6.3% 2.3% 0.016 13.6% 4.4% 0.001
6.7% 2.3% 0.009 10.2% 4.8% 0.018
31 to 365 days), and early or late ST (365 days). The p values refer to comparisons of Kaplan Meier
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1048showing an increased incidence of late stent malapposi-
tion and poor healing with DES compared with BMS
(10 –12). Our data and some of the data cited in the
preceding text support that concern.
Study limitations. Our study has several important limita-
Figure 2. Selected Univariable Correlates of Early or Late Stent Thrombosi
Kaplan-Meier estimates of cumulative frequency of early or late stent thrombo
primary percutaneous coronary intervention with stenting for ST-segment elev
with versus without STEMI due to stent thrombosis; (B) compares patients witions. Our study spans 15 years during which time treatment gtrategies with primary PCI and stenting have shown consid-
rable evolution. Different adjunctive treatments over this time
eriod could affect our outcomes and affect the incidence and
redictors of ST. Importantly, most of the stents used in this
tudy were first- or second-generation BMS and first-
o 365 Days)
) (0 to 1 year) (Academic Research Consortium deﬁnite or probable) after
myocardial infarction (STEMI) in selected subgroups. (A) Compares patients
t size 3.0 versus 3.0 mm.
Continued on the next page.s (0 t
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1049cable to current-generation stents. Our data also precede the
use of new antiplatelet agents, ticagrelor and prasugrel. We do
not have complete data on compliance with dual antiplatelet
therapy, which is an important determinant of ST. Only BMS
were implanted from 1995 to 2002, whereas both BMS and
DES were implanted from 2003 to 2009. Comparison of ST
rates for BMS and DES during these different time periods
Figure 2. Continued
(C) compares patients with Killip class III to IV versus Killip class I to II; (D) comcould introduce bias. Follow-up was obtained with the help of ielectronic medical records, which could potentially introduce
bias by obtaining follow-up in patients who are hospitalized
with ST and missing follow-up in patients without ST,
artificially increasing the frequency of ST.
Clinical implications. The relatively high incidence of ST
fter stenting for STEMI emphasizes the importance of
eveloping new strategies for preventing this complication,
patients with reperfusion time (RT) 2 h versus RT 2 h.
Continued on the next page.paresncluding better deployment techniques, newer-generation
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1050DES, bioabsorbable polymers, bioabsorbable stent plat-
forms, and better anticoagulant and antiplatelet therapies.
Prasugrel and ticagrelor have been shown to dramatically
reduce the frequency of ST in STEMI patients treated with
stents and should be used in eligible patients (21–22).
Alternative strategies include high-dose clopidogrel and
Figure 2. Continued
(E) compares patients with versus without prior myocardial infarction (MI).
Figure 3. Landmark Analysis of ST Rates With DES Versus BMS for STEMI
The curves show Kaplan-Meier estimates of deﬁnite or probable stent thrombo
BMS  bare-metal stent(s); DES  drug-eluting stent(s); STEMI  ST-segment elevatmeasurement of platelet inhibition to guide therapy in
patients not eligible for prasugrel or ticagrelor.
Patients at highest risk might be targeted for more
aggressive therapies. For example, patients with STEMI
due to ST might be considered for thrombectomy, intra-
vascular ultrasound–guided PCI, and avoidance of a new
T) rates (Academic Research Consortium criteria) at 0 to 1 and 1 year.sis (S
ion myocardial infarction.
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1051stent in selected cases. If very late ST rates are truly higher
with DES compared with BMS, the benefit of reduced
restenosis with DES might not be worth the increased risk
of very late ST, and BMS might be a more appropriate
choice in many patients with STEMI. Prolonged dual
antiplatelet therapy after the first year should also be
considered in patients with first-generation DES.
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